var data={"title":"Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6612?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Patient drug information&quot;</a> and <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709159\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Only health care providers experienced in immunosuppressive therapy and management of organ transplant patients should prescribe mycophenolate. Manage patients receiving the drug in facilities equipped and staffed with adequate laboratory and supportive medical resources. The health care provider responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious infections: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppression may lead to increased susceptibility to bacterial, viral, fungal, and protozoal infections, including opportunistic infections. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancies and serious infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Immunosuppression may lead to increased risk of development of lymphoma and other malignancies, particularly of the skin. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Embryo-fetal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Women of reproductive potential must be counseled regarding pregnancy prevention and planning.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198686\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>CellCept;</li>\n      <li>CellCept Intravenous;</li>\n      <li>Myfortic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198687\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>CellCept;</li>\n      <li>CellCept I.V.;</li>\n      <li>Myfortic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198710\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Immunosuppressant Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198690\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> May be used IV for up to 14 days; transition to oral therapy as soon as tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Autoimmune hepatitis, refractory (off-label use): </b>\n      <i>CellCept:</i> Oral: 2 g daily (Manns 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiac transplantation: </b> <i>CellCept:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 1.5 g twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 1.5 g twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatic transplantation: </b>\n      <i>CellCept:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 1.5 g twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 1 g twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lupus nephritis (off-label use):</b> <i>CellCept</i>: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Induction: 1 g twice daily for 6 months in combination with a glucocorticoid (Ong 2005) <b>or</b> 2 to 3 g daily for 6 months in combination with glucocorticoids (Hahn 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: 0.5 to 3 g daily (Contreras 2004) <b>or</b> 1 g twice daily (Dooley 2011) <b>or</b> 1 to 2 g daily (Hahn 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myasthenia gravis (off-label use): </b> <i>CellCept:</i> Oral: 1 g twice daily (range: 1 to 3 g daily) (Cahoon 2006; Ciafaloni 2001; Merriggioli 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriasis, moderate-to-severe (off-label use): </b>\n      <i>CellCept:</i> Oral: 2 to 3 g daily (Menter 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal transplant:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>CellCept:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 1 g twice daily. Doses &gt;2 g daily are not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 1 g twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Myfortic:</i> Oral: 720 mg twice daily (total daily dose: 1,440 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Systemic sclerosis (scleroderma) (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cellcept</i>: Oral: Initial: 500 mg twice daily for 1 to 4 weeks; increase to a maintenance dose of 500 to 1,500 mg twice daily as tolerated (Derk 2009; Gerbino 2008; Herrick 2017; Le 2011; Mendoza 2012; Tashkin 2016; Yilmaz 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Myfortic:</i> Oral: Initial: 360 mg twice daily for 1 week, then 720 mg twice daily (Henes 2013; Simeon-Aznar 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198703\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Renal transplant:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>CellCept:</i> Infants &ge;3 months, Children, and Adolescents:  <i>Cellcept suspension:</i> 600 mg/m<sup>2</sup>/dose twice daily; maximum dose: 1 g twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternatively, may use Cellcept solid dosage forms according to BSA as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">BSA 1.25 to 1.5 m<sup>2</sup>: 750 mg capsule twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">BSA &gt;1.5 m<sup>2</sup>: 1 g capsule or tablet twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Myfortic</i>: Children &ge;5 years and Adolescents: Usual dosage: 400 mg/m<sup>2</sup>/dose twice daily; maximum dose: 720 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">BSA &lt;1.19 m<sup>2</sup>: Use of this formulation is not recommended </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">BSA 1.19 to 1.58 m<sup>2</sup>: 540 mg twice daily (maximum: 1080 mg daily) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">BSA &gt;1.58 m<sup>2</sup>: 720 mg twice daily (maximum: 1440 mg daily) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198691\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Dosage is the same as younger patients, however, dosing should be cautious due to possibility of increased hepatic, renal, or cardiac dysfunction. Elderly patients may be at an increased risk of certain infections, gastrointestinal hemorrhage, and pulmonary edema, as compared to younger patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198692\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Renal transplant: GFR &lt;25 mL/minute/1.73 m<sup>2</sup> in patients outside the immediate post-transplant period: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: Doses of &gt;1 g administered twice daily should be avoided; patients should also be carefully observed; no dose adjustments are needed in renal transplant patients experiencing delayed graft function postoperatively </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: No dose adjustments are needed in renal transplant patients experiencing delayed graft function postoperatively; however, monitor carefully for potential concentration dependent adverse events</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiac or liver transplant: No data available; mycophenolate may be used in cardiac or hepatic transplant patients with severe chronic renal impairment if the potential benefit outweighs the potential risk. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Autoimmune disease (off-label use): There have been no specific dosage adjustments identified, although use of lower doses may be required.  MPA exposure appears to be inversely related to renal function (Abd Rahman, 2013); monitor closely for efficacy and adverse effects, especially in patients with end-stage renal disease (Haubitz, 2002; MacPhee, 2000). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemodialysis: Not removed; supplemental dose is not necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peritoneal dialysis: Supplemental dose is not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198693\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment is recommended for renal patients with severe hepatic parenchymal disease; however, it is not currently known whether dosage adjustments are necessary for hepatic disease with other etiologies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3022884\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Neutropenia (ANC &lt;1.3 x 10<sup>3</sup>/&mu;L): Dosing should be interrupted or the dose reduced, appropriate diagnostic tests performed and patients managed appropriately</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198659\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as mofetil: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: 250 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as mofetil hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept Intravenous: 500 mg (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as mofetil: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: 200 mg/mL (160 mL) [contains aspartame, methylparaben, sorbitol, soybean lecithin; mixed fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/mL (160 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as mofetil: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: 500 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral, as mycophenolic acid: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: 180 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: 360 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 180 mg, 360 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198644\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874743\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Myfortic: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM172735.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQaIxh8Hco9F8HyORMH6RfMg==&amp;TOPIC_ID=9670\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM172735.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CellCept: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM170919.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQ0AIED7JFY5eSqJp8L4eB4w==&amp;TOPIC_ID=9670\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM170919.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198662\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Oral dosage formulations (tablet, capsule, suspension) should be administered on an empty stomach (1 hour before or 2 hours after meals) to avoid variability in MPA absorption. The oral solution may be administered via a nasogastric tube (minimum 8 French, 1.7 mm interior diameter); oral suspension should not be mixed with other medications. Delayed release tablets should not be crushed, cut, or chewed. Cellcept may be administered with food in stable renal transplant patients when necessary. If a dose is missed, administer as soon as it is remembered. If it is close to the next scheduled dose, skip the missed dose and resume at next regularly scheduled time; do not double a dose to make up for a missed dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Intravenous solutions should be administered over at least 2 hours (either peripheral or central vein); do <b>not</b> administer intravenous solution by rapid or bolus injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132818\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) when compounding. Double gloving and a gown are required during IV administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198660\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Organ transplantation:</b> Prophylaxis of organ rejection concomitantly with cyclosporine and corticosteroids in patients receiving allogeneic renal (CellCept, Myfortic), cardiac (CellCept), or hepatic (CellCept) transplants</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469168\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute graft-versus-host disease, refractory (treatment); Chronic graft-versus-host disease, refractory (treatment); Graft-versus-host disease (prevention); Hepatitis (autoimmune, refractory); Lupus nephritis; Myasthenia gravis; Psoriasis (moderate-to-severe); Rejection in heart transplant patients (recurrent or persistent); Rejection in liver transplant patients unable to tolerate tacrolimus or cyclosporine due to toxicity; Systemic sclerosis (scleroderma)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708052\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198651\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Data for incidence &gt;20% as reported in adults following oral dosing of CellCept alone in renal, cardiac, and hepatic allograft rejection studies. Profile in 3% to &lt;20% range reflects use in combination with cyclosporine and corticosteroids. In general, lower doses used in renal rejection patients had less adverse effects than higher doses. Rates of adverse effects were similar for each indication, except for those unique to the specific organ involved. The type of adverse effects observed in pediatric patients was similar to those seen in adults, with the exception of abdominal pain, anemia, diarrhea, fever, hypertension, infection, pharyngitis, respiratory tract infection, sepsis, and vomiting, which were more frequent in pediatric patients; lymphoproliferative disorder was the only type of malignancy observed. Percentages of adverse reactions were similar in studies comparing CellCept to Myfortic in patients following renal transplant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;20%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (28% to 78%), hypotension (33%), peripheral edema (27% to 64%), edema (27% to 28%), chest pain (26%), tachycardia (20% to 22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (31% to 76%), headache (16% to 54%), insomnia (41% to 52%), dizziness (29%), anxiety (28%), paresthesia (21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia (44% to 47%), hypercholesterolemia (41%), hypomagnesemia (39%), hypokalemia (32% to 37%), hypocalcemia (30%), increased lactate dehydrogenase (23%), hyperkalemia (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (25% to 63%), nausea (20% to 55%), diarrhea (31% to 51%), constipation (19% to 41%), vomiting (33% to 34%), anorexia (25%), dyspepsia (22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (37%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (23% to 46%), anemia (26% to 43%), leukocytosis (22% to 41%), thrombocytopenia (24% to 38%), hypochromic anemia (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (25%), ascites (24%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (27%), infection (18% to 27%), candidiasis (17% to 22%), herpes simplex infection (10% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (35% to 47%), weakness (35% to 43%), tremor (24% to 34%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (39%), increased blood urea nitrogen (35%), renal function abnormality (22% to 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (31% to 37%), respiratory tract infection (22% to 37%), pleural effusion (34%), cough (31%), pulmonary disease (22% to 30%), sinusitis (26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (21% to 52%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">3% to &lt;20%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Angina pectoris, arterial thrombosis, atrial fibrillation, atrial flutter, bradycardia, cardiac arrhythmia, cardiac failure, extrasystoles, facial edema, increased venous pressure, orthostatic hypotension, palpitations, pericardial effusion, peripheral vascular disorder, supraventricular extrasystole, supraventricular tachycardia, syncope, thrombosis, vasodilatation, vasospasm, ventricular premature contractions, ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormality in thinking, agitation, confusion, delirium, depression, drowsiness, emotional lability, hallucination, hypertonia, hypoesthesia, malaise, myasthenia, nervousness, neuropathy, psychosis, seizure, vertigo, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris, alopecia, cellulitis, dermal ulcer, diaphoresis, fungal dermatitis, pallor, pruritus, skin hypertrophy, vesiculobullous dermatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Acidosis, albuminuria, alkalosis, Cushing's syndrome, dehydration, diabetes mellitus, gout, hirsutism, hypercalcemia, hyperphosphatemia,  hyperlipidemia, hypervolemia, hypochloremia, hypoglycemia, hyponatremia, hypophosphatemia, hypoproteinemia, hypothyroidism, hypovolemia, increased gamma-glutamyl transferase, increased thirst, parathyroid disease, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Mucocutaneous candidiasis (16% to 18%), cholangitis, dysphagia, enlargement of abdomen, esophagitis, flatulence, gastric disease, gastric ulcer, gastritis, gastroenteritis, gastrointestinal hemorrhage, GI moniliasis, gingival hyperplasia, gingivitis, hernia, hiccups, intestinal obstruction, melena, oral candidiasis, oral mucosa ulcer, peritonitis, stomatitis, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria, hematuria, impotence, nocturia, oliguria, pelvic pain, prostatic disease, scrotal edema, urinary frequency, urinary incontinence, urinary retention, urinary tract abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Blood coagulation disorder, bruise, hemophthalmos, hemorrhage, neoplasm, neutropenia, pancytopenia, petechia, polycythemia, prolonged prothrombin time, prolonged partial thromboplastin time, skin carcinoma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Cholestatic jaundice, hepatic insuffiency, hepatitis, hyperbilirubinemia, increased serum alkaline phosphatase, increased serum transaminases, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Cytomegalovirus disease (viremia/syndrome: 12% to 14%; tissue invasive disease: 6% to 12%), herpes zoster (cutaneous disease: 4% to 10%), abscess (local), infection (of ileus)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, leg cramps, myalgia, neck pain, osteoporosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Abnormal lacrimation, amblyopia, cataract, conjunctivitis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Deafness, ear disease, otalgia, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Hydronephrosis, increased serum creatinine, pyelonephritis, renal failure, renal tubular necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea, asthma, atelectasis, bronchitis, epistaxis, flu-like symptoms, hemoptysis, hyperventilation, hypoxia, increased bronchial secretions, pharyngitis, pneumonia, pneumothorax, pulmonary edema, pulmonary hypertension, respiratory acidosis, respiratory tract infection (moniliasis), rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Abnormal healing, cyst, fever and chills</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Atypical mycobacterial infection, bronchiectasis (Boddana 2011, Rook 2006), colitis, endocarditis (infectious), gastrointestinal perforation, hypogammaglobulinemia (Boddana 2011; Keven 2003; Robertson 2009), interstitial pulmonary disease, lymphoproliferative disorder, malabsorption (intestinal villous atrophy), malignant lymphoma, malignant neoplasm, meningitis, pancreatitis, progressive multifocal leukoencephalopathy, pulmonary fibrosis, pure red cell aplasia, renal disease (BK virus-associated), tuberculosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198665\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to mycophenolate mofetil, mycophenolic acid, mycophenolate sodium, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cellcept: Intravenous formulation is also contraindicated in patients who are allergic to polysorbate 80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Pregnancy; women of childbearing potential and not using highly effective contraceptive methods; women of childbearing potential not providing a pregnancy test result; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198648\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Risk for bacterial, viral, fungal, and protozoal infections, including opportunistic infections, is increased with immunosuppressant therapy</b>; infections may be serious and potentially fatal. Due to the risk of oversuppression of the immune system, which may increase susceptibility to infection, combination immunosuppressant therapy should be used with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; New or reactivated viral infections: Polyomavirus associated nephropathy (PVAN), JC virus-associated progressive multifocal leukoencephalopathy (PML), cytomegalovirus (CMV) infections, and reactivation of hepatitis B (HBV) or hepatitis C (HCV) have been reported with use. A reduction in immunosuppression should be considered for patients with new or reactivated viral infections; however, in transplant recipients, the risk that reduced immunosuppression presents to the functioning graft should also be considered. PVAN, primarily from activation of BK virus, may lead to the deterioration of renal function and/or renal graft loss. PML, a potentially fatal condition, commonly presents with apathy, ataxia, cognitive deficiencies, confusion, and hemiparesis. Risk factors for development of PML include treatment with immunosuppressants and immune function impairment; consultation with a neurologist should be considered in any patient with neurological symptoms receiving immunosuppressants. Risk of CMV viremia or disease is increased in transplant recipients CMV seronegative at the time of transplant who receive a graft from a CMV seropositive donor; however, routine approaches to limiting CMV exist and should be utilized. In patients infected with HBV or HCV, viral reactivation may occur; these patients should be monitored for signs of active HBV or HCV.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lymphoproliferative disorders: <b>[US Boxed Warning]: Risk of development of lymphoma and skin malignancy is increased.</b> The risk for malignancies is related to intensity/duration of therapy. Patients should be monitored appropriately, instructed to limit exposure to sunlight/UV light to decrease the risk of skin cancer, and given supportive treatment should these conditions occur. Post-transplant lymphoproliferative disorder related to EBV infection has been reported in immunosuppressed organ transplant patients; risk is highest in EBV seronegative patients (including many young children).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neutropenia: Neutropenia (including severe neutropenia) may occur, requiring dose reduction or interruption of treatment (risk greater from day 31-180 post-transplant).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pure red cell aplasia (PRCA): PRCA, a type of anemia which can range from subclinical to severe, has been reported in patients receiving mycophenolate concomitantly with other immunosuppressive agents (eg, tacrolimus, cyclosporine, corticosteroids). Symptoms may include fatigue, lethargy, or pallor. Although not precisely known, risk factors for the development of PRCA may include immunosuppression and treatment with immunosuppressant therapy. Dose reduction or discontinuation of immunosuppressive therapy may reverse PRCA; however, in transplant recipients, the risk of reduced immunosuppression and graft rejection should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disorders: Use may rarely be associated with gastric or duodenal ulcers, GI bleeding and/or perforation. Use caution in patients with active serious digestive system disease; patients with active peptic ulcers were not included in clinical studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoxanthine-guanine phosphoribosyltransferase deficiency: Theoretically, use should be avoided in patients with the rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (such as Lesch-Nyhan or Kelley-Seegmiller syndrome).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment as toxicity may be increased; may require dosage adjustment in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Non-interchangeability of dosage forms: Mycophenolate sodium and mycophenolate mofetil should <b>not</b> be used interchangeably without health care provider supervision because the rate of absorption following the administration of these two products is not equivalent. Single dose pharmacokinetic studies in adult renal transplant patients suggest that bioavailability is similar between oral mycophenolate mofetil (1,000 mg) and delayed release mycophenolic acid (720 mg) (Arns 2005). In clinical trials, comparative efficacy and safety profiles have been observed in adult renal transplant patients randomized to either oral mycophenolate mofetil (1,000 mg twice daily) or delayed release mycophenolic acid (720 mg twice daily) (Budde, 2004; 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Some dosage forms may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Mycophenolate is associated with an increased risk of congenital malformations and first trimester pregnancy loss when used by pregnant women. Females of reproductive potential must be counseled about pregnancy prevention and planning.</b> Alternative agents should be considered for women planning a pregnancy. Females of reproductive potential should have a negative pregnancy test with a sensitivity of &ge;25 milliunits/mL immediately before therapy and the test should be repeated 8-10 days later. Pregnancy tests should be repeated during routine follow-up visits. Acceptable forms of contraception should be used during treatment and for 6 weeks after therapy is discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of a physician experienced in immunosuppressive therapy. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Live attenuated vaccines should be avoided during use; vaccinations may be less effective during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: Intravenous solutions should be given over at least 2 hours; <b>never</b> administer intravenous solution by rapid or bolus injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299731\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT3, OATP1B1/SLCO1B1, OATP1B3/SLCO1B3, UGT1A10, UGT1A8, UGT1A9, UGT2B7</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198653\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9670&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acyclovir-Valacyclovir: May increase the serum concentration of Mycophenolate. Mycophenolate may increase the serum concentration of Acyclovir-Valacyclovir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Mycophenolate. Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.<b> Exceptions: </b>Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Mycophenolate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholestyramine Resin: May decrease the serum concentration of Mycophenolate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May decrease the serum concentration of Mycophenolate. Specifically, cyclosporine may decrease concentrations of the active metabolite mycophenolic acid. Management: Mycophenolate requirements may be greater in patients receiving cyclosporine. Monitor mycophenolate dosing and response to therapy particularly closely when adjusting concurrent cyclosporine (starting, stopping, or changing dose).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Mycophenolate may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination.  Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: Mycophenolate may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Mycophenolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May increase the serum concentration of Mycophenolate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Mycophenolate. Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Systemic): May decrease the serum concentration of Mycophenolate. Specifically, metronidazole may decrease concentrations of the active metabolite of mycophenolate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Mycophenolate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Mycophenolate may decrease the serum concentration of Progestins (Contraceptive).  Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Mycophenolate. Specifically, rifamycin derivatives may decrease the concentration of the active metabolite mycophenolic acid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the serum concentration of Mycophenolate. Management: Administer mycophenolate at least 2 hours prior to sevelamer administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198682\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases C<sub>max</sub> of MPA by 40% following CellCept administration and 33% following Myfortic use; the extent of absorption is not changed. Management: Take CellCept or Myfortic on an empty stomach to decrease variability; however, Cellcept may be taken with food if necessary in stable renal transplant patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198655\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198668\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Mycophenolate is associated with an increased risk of congenital malformations and first trimester pregnancy loss when used by pregnant women. Females of reproductive potential must be counseled about pregnancy prevention and planning.</b> Alternative agents with less potential for embryofetal toxicity should be considered for women planning a pregnancy. The following congenital malformations have been reported following exposure during pregnancy: External ear abnormalities, cleft lip and palate, anomalies of the distal limbs, heart, esophagus, kidney, and nervous system. The combination of ear, eye, and lip/palate abnormalities has been identified as mycophenolate embryopathy (Perez-Aytes 2017). Spontaneous abortions have also been noted.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Females of reproductive potential (girls who have entered puberty and women with a uterus who have not passed through clinically confirmed menopause) should have a negative pregnancy test with a sensitivity of &ge;25 milliunits/mL immediately before mycophenolate therapy and the test should be repeated 8 to 10 days later. Pregnancy tests should then be repeated during routine follow-up visits. Acceptable forms of contraception should be used during treatment and for 6 weeks after therapy is discontinued. The effectiveness of hormonal contraceptive agents may be affected by mycophenolate.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Current guidelines recommend that pregnancy be delayed following a kidney transplant until 1 year has passed without an acute rejection; this time period may be adjusted as clinically appropriate. Women planning a pregnancy and who are already taking mycophenolate following a kidney transplant should be switched to a different medication and mycophenolate should be discontinued for at least 6 weeks before pregnancy is attempted (KDIGO 2009). Mycophenolate is not recommended for the treatment of psoriasis in pregnant women (Menter 2009). Mycophenolate should not be used during pregnancy in women with lupus nephritis; women who become pregnant during mycophenolate therapy should be switched to a different medication (KDIGO 2012). For women with lupus nephritis taking mycophenolate and who are planning a pregnancy, mycophenolate should be discontinued at least 6 weeks prior to trying to conceive (Hahn 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers should report female exposures to mycophenolate during pregnancy or within 6 weeks of discontinuing therapy to the Mycophenolate Pregnancy Registry (800-617-8191).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198669\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if mycophenolate is present in human milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug (during therapy or within 6 weeks after treatment is complete), taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198670\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198657\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Complete blood count (weekly for first month, twice monthly during months 2 and 3, then monthly thereafter through the first year); renal and liver function; signs and symptoms of organ rejection; signs and symptoms of bacterial, fungal, protozoal, new or reactivated viral, or opportunistic infections; neurological symptoms (eg, hemiparesis, confusion, cognitive deficiencies, ataxia) suggestive of PML, pregnancy test (sensitivity of &ge;25 milliunits/mL; immediately prior to initiation and 8 to 10 days later in females of childbearing potential, followed by repeat tests during therapy); monitor skin (for lesions suspicious of skin cancer); monitor for signs of lymphoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198647\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">MPA exhibits a cytostatic effect on T and B lymphocytes. It is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) which inhibits <i>de novo</i> guanosine nucleotide synthesis. T and B lymphocytes are dependent on this pathway for proliferation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198664\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Peak effect: Correlation of toxicity or efficacy is still being developed, however, one study indicated that 12-hour AUCs &gt;40 mcg/mL/hour were correlated with efficacy and decreased episodes of rejection </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and extensive; early post-transplant period mycophenolic acid (MPA) AUC values are lower (~45% to 53%) than later post-transplant period (&gt;3 months) MPA AUC values in both pediatric patients and adults</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Myfortic: 93%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: MPA: Oral: 4 L/kg; IV: 3.6 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: MPA: Oral: 54 L (at steady state); 112 L (elimination phase)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: MPA: &gt;97%, MPAG 82% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic and via GI tract; CellCept is completely hydrolyzed in the liver to mycophenolic acid (MPA; active metabolite); enterohepatic recirculation of MPA may occur; MPA is glucuronidated to MPAG (inactive metabolite) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: CellCept: 80.7% to 94%; enterohepatic recirculation contributes to MPA concentration (Staatz 2007); two 500 mg tablets have been shown to be bioequivalent to four 250 mg capsules or 1,000 mg of oral suspension; Myfortic: 72% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: MPA: Oral: 18 hours; IV: 17 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: MPA: Oral: 8 to 16 hours; MPAG: 13 to 17 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: MPA:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: 1 to 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: 1.5 to 2.75 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: MPA: Urine (&lt;1%), feces (6%); MPAG: Urine (87%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: MPA: Urine (3%), feces; MPAG: Urine (&gt;60%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198667\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (CellCept Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $1,079.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Mycophenolate Mofetil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $396.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CellCept Intravenous Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $129.57</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Mycophenolate Mofetil HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $116.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (CellCept Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (160 mL): $1,657.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Mycophenolate Mofetil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (160 mL): $1,367.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Mycophenolate Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (120): $548.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (120): $1,096.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Myfortic Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (120): $749.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (120): $1,498.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (CellCept Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $2,159.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mycophenolate Mofetil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $792.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198671\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Accocept (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Atajec (PH);</li>\n      <li>Celguard (BD);</li>\n      <li>Cellcept (AE, AT, BH, CL, CN, CU, CY, CZ, DK, ES, HR, HU, IS, JO, JP, KW, LB, LK, LT, LV, NO, PL, QA, RO, SA, VN);</li>\n      <li>CellCept (BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, HK, IE, JM, KE, LR, MA, ML, MR, MT, MU, MW, NE, NG, NZ, PY, SC, SD, SI, SK, SL, SN, SR, TN, TR, TT, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Cellmune (IN);</li>\n      <li>Ceptolate (AU);</li>\n      <li>Graftcept (BD);</li>\n      <li>Imulate (AU, NZ);</li>\n      <li>Linfonex (CL, EC, PY);</li>\n      <li>Micocept (HK);</li>\n      <li>Micoflavin (EC);</li>\n      <li>Mofilet (LK);</li>\n      <li>Mowel (AT);</li>\n      <li>Myclausen (IE);</li>\n      <li>Mycofit (ET);</li>\n      <li>Mycokem (PH);</li>\n      <li>Mycolat (IE);</li>\n      <li>Mycopen (PH);</li>\n      <li>Mycotil (BD);</li>\n      <li>Myfenax (ES, IE, LK, MT, PL);</li>\n      <li>Myfortic (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CU, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HN, HR, ID, IE, IL, IS, IT, JO, KR, KW, LB, LK, LT, LV, MT, MX, MY, NL, NO, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY, VE, VN);</li>\n      <li>Myotec (PH);</li>\n      <li>Nuodun (CN);</li>\n      <li>Phenocept (BD);</li>\n      <li>Suprimun (CL);</li>\n      <li>Transfonex (VN);</li>\n      <li>Unorem (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abd Rahman AN, Tett SE, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. <i>Clin Pharmacokinet</i>. 2013;52(5):303-331.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/23475567/pubmed\" target=\"_blank\" id=\"23475567\">23475567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19443659\"></a>Alousi AM, Weisdorf DJ, Logan BR, et al, &ldquo;Etanercept, Mycophenolate, Denileukin, or Pentostatin Plus Corticosteroids for Acute Graft-Versus-Host Disease: A Randomized Phase 2 Trial from the Blood and Marrow Transplant Clinical Trials Network,&rdquo; , <i>Blood</i>2009, 114(3):511-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/19443659/pubmed\" target=\"_blank\" id=\"19443659\">19443659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. <i>Clin Transplant</i>. 2005;19(2):199-206.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/15740555/pubmed\" target=\"_blank\" id=\"15740555\">15740555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bertsias G, Ioannidis JP, Boletis J, et al, &ldquo;EULAR Recommendations for the Management of Systemic Lupus Erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics,&rdquo; <i>Ann Rheum Dis</i>, 2008, 67(2):195-205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/17504841/pubmed\" target=\"_blank\" id=\"17504841\">17504841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boddana P, Webb LH, Unsworth J, Brealey M, Bingham C, Harper SJ. Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: an emerging clinical phenomenon? <i>Clin Transplant</i> 2011;25:417-419.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/20438577/pubmed\" target=\"_blank\" id=\"20438577\">20438577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Budde K, Glander P, Diekmann F, et al. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients. <i>Transplant Proc</i>. 2004;36(2 suppl):524S-527S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/15041401/pubmed\" target=\"_blank\" id=\"15041401\">15041401</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16403848\"></a>Cahoon WD Jr and Kockler DR, &ldquo;Mycophenolate Mofetil Treatment of Myasthenia Gravis,&rdquo; <i>Ann Pharmacother</i>, 2006, 40(2):295-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/16403848/pubmed\" target=\"_blank\" id=\"16403848\">16403848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    CellCept (mycophenolate mofetil) [prescribing information]. South San Francisco, CA: Genentech USA Inc; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    CellCept (mycophenolate mofetil ) [product monograph]. Mississauga, Ontario, Canada: Hoffman-La Roche Ltd; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chaudhry V, Cornblath DR, Griffin JW, et al, &ldquo;Mycophenolate Mofetil: A Safe and Promising Immunosuppressant in Neuromuscular Diseases,&rdquo; <i>Neurology</i>, 2001, 56(1):94-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/11148242/pubmed\" target=\"_blank\" id=\"11148242\">11148242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11148243\"></a>Ciafaloni E, Massey JM, Tucker-Lipscomb B, et al, &ldquo;Mycophenolate Mofetil for Myasthenia Gravis: An Open-Label Pilot Study,&rdquo; <i>Neurology</i>, 2001, 56(1):97-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/11148243/pubmed\" target=\"_blank\" id=\"11148243\">11148243</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14999109\"></a>Contreras G, Pardo V, Leclercq B, et al, &ldquo;Sequential Therapies for Proliferative Lupus Nephritis,&rdquo; <i>N Engl J Med</i>, 2004, 350(10):971-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/14999109/pubmed\" target=\"_blank\" id=\"14999109\">14999109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19846575\"></a>Derk CT, Grace E, Shenin M, et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. <i>Rheumatology.</i> 2009;48:1595-1599. doi: 10.1093/rheumatology/kep295.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/19846575/pubmed\" target=\"_blank\" id=\"19846575\">19846575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22087680\"></a>Dooley MA, Jayne D, Ginzler EM, et al, &ldquo;Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis,&rdquo; <i>N Engl J Med</i>, 2011, 365(20):1886-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/22087680/pubmed\" target=\"_blank\" id=\"22087680\">22087680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ettenger R, Warshaw B, Menster M, et al, &ldquo;Mycophenolate Mofetil (MMF) in Pediatric (Ped) Renal Transplantation (Tx): A Report of the Ped MMF Study Group (PMMSG),&rdquo; 1996:97 [abstract 97 from ASTP Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furlong T, Martin P, Flowers ME, et al, &ldquo;Therapy With Mycophenolate Mofetil for Refractory Acute and Chronic GVHD,&rdquo; <i>Bone Marrow Transplant</i>, 2009, 44(11):739-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/19377515/pubmed\" target=\"_blank\" id=\"19377515\">19377515</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gabardi S, Tran JL, and Clarkson MR, &ldquo;Enteric-Coated Mycophenolate Sodium,&rdquo; <i>Ann Pharmacother</i>, 2003, 37(11):1685-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/14565799/pubmed\" target=\"_blank\" id=\"14565799\">14565799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18071023\"></a>Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. <i>CHEST.</i> 2008;133:455-460. doi: 10.1378/chest.06-2861.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/18071023/pubmed\" target=\"_blank\" id=\"18071023\">18071023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gipson DS, Massengill SF, Yao L, et al, &quot;Management of Childhood Onset Nephrotic Syndrome,&quot; <i>Pediatrics</i>, 2009, 124(2):747-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/19651590/pubmed\" target=\"_blank\" id=\"19651590\">19651590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hahn BH, McMahon MA, Wilkinson A, et al, &quot;American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis,&quot; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(6):797-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/22556106/pubmed\" target=\"_blank\" id=\"22556106\">22556106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haubitz M, de Groot K. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. <i>Clin Nephrol</i>. 2002;57(6):421-424.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/12078944/pubmed\" target=\"_blank\" id=\"12078944\">12078944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23307324\"></a>Henes JC, Horger M, Amberger C, et al. Enteric-coated mycophenolate sodium for progressive systemic sclerosis&mdash;a prospective open-label study with CT histography for monitoring of pulmonary fibrosis. <i>Clin Rheumatol.</i> 2013;32:673-678. doi: 10.1007/s10067-012-2155-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/23307324/pubmed\" target=\"_blank\" id=\"23307324\">23307324</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28188239\"></a>Herrick AL, Pan X, Peytrignet S, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Ann Rheum Dis. </i>2017;76:1207-1218. doi: 10.1136/annrheumdis-2016-210503.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/28188239/pubmed\" target=\"_blank\" id=\"28188239\">28188239</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keven K, Sahin M, Kutlay S, Sengul S, Erturk S, Ersoz S, Erbay B. Immunoglobulin deficiency in kidney allograft recipients: comparative effects of mycophenolate mofetil and azathioprine. <i>Transpl Infect Dis</i>. 2003;5:181-186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/14987202/pubmed\" target=\"_blank\" id=\"14987202\">14987202</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. <i>Am J Transplant</i>. 2009;9(suppl 3):S1-S155. doi: 10.1111/j.1600-6143.2009.02834.x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/19845597/pubmed\" target=\"_blank\" id=\"19845597\">19845597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney inter., Suppl. 2012;2(2):139&ndash;274. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-GN-Guideline.pdf. Accessed July 27, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8061021\"></a>Kirklin JK1, Bourge RC, Naftel DC, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. <i>J Heart Lung Transplant</i>. 1994;13(3):444-450.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/8061021/pubmed\" target=\"_blank\" id=\"8061021\">8061021</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21378404\"></a>Le EN, Wigley FM, Shah AA, et al. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. <i>Ann Rheum Dis.</i> 2011;70(6):1104-1107. doi:10.1136/ard.2010.142000.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/21378404/pubmed\" target=\"_blank\" id=\"21378404\">21378404</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8918281\"></a>Lipsky JJ. Mycophenolate mofetil. <i>Lancet.</i> 1996;348(9038):1357-1359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/8918281/pubmed\" target=\"_blank\" id=\"8918281\">8918281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacPhee IA, Spreafico S, Bewick M, et al. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. <i>Kidney Int</i>. 2000; 57(3):1164-1168.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/10720968/pubmed\" target=\"_blank\" id=\"10720968\">10720968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manns MP, Czaja AJ, Gorham JD, et al, &ldquo;Diagnosis and Management of Autoimmune Hepatitis,&rdquo; <i>Hepatology</i>, 2010, 51(6):2193-213.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/20513004/pubmed\" target=\"_blank\" id=\"20513004\">20513004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22467932\"></a>Mendoza FA, Nagle SJ, Lee JB, et al. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. <i>J Rheumatol.</i> 2012;39:1241&ndash;1247. doi: 10.3899/jrheum.111229.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/22467932/pubmed\" target=\"_blank\" id=\"22467932\">22467932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19493586\"></a>Menter A, Korman NJ, Elmets CA, et al, &ldquo;Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 4. Guidelines of Care for the Management and Treatment of Psoriasis With Traditional Systemic Agents,&rdquo; <i>J Am Acad Dermatol</i>, 2009, 61(3):451-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/19493586/pubmed\" target=\"_blank\" id=\"19493586\">19493586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14638974\"></a>Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al, &ldquo;Mycophenolate Mofetil for Myasthenia Gravis: An Analysis of Efficacy, Safety, and Tolerability,&rdquo; <i>Neurology</i>, 2003, 61(10):1438-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/14638974/pubmed\" target=\"_blank\" id=\"14638974\">14638974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myfortic (mycophenolate sodium) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myfortic (mycophenolate sodium) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16899504\"></a>Nihtyanova SI, Brough GM, Black CM, et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis&mdash;a retrospective analysis. <i>Rheumatology. </i>2007;46:442&ndash;445. doi: 10.1093/rheumatology/kel244.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/16899504/pubmed\" target=\"_blank\" id=\"16899504\">16899504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16221103\"></a>Ong LM, Hooi LS, Lim TO, et al, &ldquo;Randomized Controlled Trial of Pulse Intravenous Cyclophosphamide versus Mycophenolate Mofetil in the Induction Therapy of Proliferative Lupus Nephritis,&rdquo; <i>Nephrology (Carlton)</i>, 2005, 10(5):504-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/16221103/pubmed\" target=\"_blank\" id=\"16221103\">16221103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27639443\"></a>Perez-Aytes A, Marin-Reina P, Boso V, Ledo A, Carey JC, Vento M. Mycophenolate mofetil embryopathy: A newly recognized teratogenic syndrome. <i>Eur J Med Genet</i>. 2017;60(1):16-21. doi: 10.1016/j.ejmg.2016.09.014.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/27639443/pubmed\" target=\"_blank\" id=\"27639443\">27639443</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robertson J, Elidemir O, Saz EU, et al. Hypogammaglobulinemia: incidence, risk factors, and outcomes following pediatric lung transplantation. <i>Pediatr Transplant</i>. 2009;13:754-759.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/19067916/pubmed\" target=\"_blank\" id=\"19067916\">19067916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rook M, Postma DS, van der Jagt EJ, et al. Mycophenolate mofetil and bronchiectasis in kidney transplant patients: a possible relationship. <i>Transplantation</i>. 2006;81:287-289.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/16436974/pubmed\" target=\"_blank\" id=\"16436974\">16436974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19589481\"></a>Sabry W, Le Blanc R, Labb&eacute; AC, et al, &ldquo;Graft-Versus-Host Disease Prophylaxis With Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients is Associated With Very Low Incidence of GVHD and Nonrelapse Mortality,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2009, 15(8):919-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/19589481/pubmed\" target=\"_blank\" id=\"19589481\">19589481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salvadori M, Holzer H, de Mattos A, et al; ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. <i>Am J Transplant</i>. 2004;4(2):231-236.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21832958\"></a>Schmeding M, Kiessling A, Neuhaus R, et al, &quot;Mycophenolate Mofetil Monotherapy in Liver Transplantation: 5-year Follow-up of a Prospective Randomized Trial,&quot; <i>Transplantation</i>, 2011, 92(8):923-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/21832958/pubmed\" target=\"_blank\" id=\"21832958\">21832958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaw LM, Sollinger HW, Halloran P, et al, &ldquo;Mycophenolate Mofetil: A Report of the Consensus Panel,&rdquo; <i>Ther Drug Monit</i>, 1995, 17(6):690-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/8588243/pubmed\" target=\"_blank\" id=\"8588243\">8588243</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sifontis NM, Coscia LA, Constantinescu S, et al, &ldquo;Pregnancy Outcomes in Solid Organ Transplant Recipients With Exposure to Mycophenolate Mofetil or Sirolimus,&rdquo; <i>Transplantation</i>, 2006, 82(12):1698-702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/17198262 /pubmed\" target=\"_blank\" id=\"17198262 \">17198262 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21881859\"></a>Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. <i>Clin Rheumatol.</i> 2011;30:1393&ndash;1398. doi: 10.1007/s10067-011-1823-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/21881859/pubmed\" target=\"_blank\" id=\"21881859\">21881859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sollinger HW, &ldquo;Mycophenolate Mofetil for the Prevention of Acute Rejection in Primary Cadaveric Renal Allograft Recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group,&rdquo; <i>Transplantation</i>, 1995, 60:225-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/7645033/pubmed\" target=\"_blank\" id=\"7645033\">7645033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27469583\"></a>Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respir Med.</i> 2016;4:708&ndash;719. doi: 10.1016/S2213-2600(16)30152-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/27469583/pubmed\" target=\"_blank\" id=\"27469583\">27469583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vogelsang GB, and Arai S, &ldquo;Mycophenolate Mofetil for the Prevention and Treatment of Graft-Versus-Host Disease Following Stem Cell Transplantation: Preliminary Findings,&rdquo; <i> Bone Marrow Transplant</i>, 2001, 27(12):1255-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/11548843/pubmed\" target=\"_blank\" id=\"11548843\">11548843</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolff D, Schleuning M, von Harsdorf S, et al, &ldquo;Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2010, 17(1):1-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/20685255/pubmed\" target=\"_blank\" id=\"20685255\">20685255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24864029\"></a>Yilmaz N, Can M, Kocakaya D, et al. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series. <i>Int J Rheum Dis.</i> 2014;17(8):923-928. doi: 10.1111/1756-185X.12399.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/24864029/pubmed\" target=\"_blank\" id=\"24864029\">24864029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhu B, Chen N, Lin Y, et al, &ldquo;Mycophenolate Mofetil in Induction and Maintenance Therapy of Severe Lupus Nephritis: A Meta-Analysis of Randomized Controlled Trials,&rdquo; <i>Nephrol Dial Transplant</i>, 2007, 22(7):1933-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information/abstract-text/17405792/pubmed\" target=\"_blank\" id=\"17405792\">17405792</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9670 Version 234.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709159\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F198686\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F198687\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F198710\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F198690\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F198703\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F198691\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F198692\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F198693\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F3022884\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F198659\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F198644\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874743\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F198662\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132818\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F198660\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469168\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25708052\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F198651\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F198665\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F198648\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299731\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F198653\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F198682\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F198655\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F198668\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F198669\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F198670\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F198657\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F198647\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F198664\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F198667\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F198671\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9670|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-patient-drug-information\" class=\"drug drug_patient\">Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Patient drug information</a></li><li><a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information\" class=\"drug drug_pediatric\">Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Pediatric drug information</a></li></ul></div></div>","javascript":null}